GlassScriptPhysician profile
Suresh Karne
NPI 1366534307
$11,698.86
in general payments reported to CMS, 2019-2025
40 companies · $2,219 in 2025
The $2,219 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $402 · 2021: $1,053 · 2022: $2,123 · 2023: $2,478 · 2024: $2,292 · 2025: $2,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,852 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,851.85 |
| Education | $136.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,034.52 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,363.30 | 2019-2025 | Relistor, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $1,324.58 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $1,081.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $828.36 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $523.90 | 2019-2025 | Livdelzi |
| Novo Nordisk INC | $346.91 | 2022-2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $267.83 | 2019-2024 | Rebyota, Clenpiq, Cimzia |
| Qol Medical, LLC | $245.51 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $188.88 | 2019-2024 | Linzess |
| Evoke Pharma, INC. | $180.73 | 2022-2023 | Gimoti |
| Genzyme Corporation | $164.01 | 2023-2025 | |
| Fujifilm Healthcare Americas Corporation | $150.83 | 2022 | |
| Lilly USA, LLC | $141.52 | 2020-2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.49 | 2019-2023 | Cyltezo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $128.56 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Axsome Therapeutics, INC. | $124.32 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $122.17 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $115.31 | 2021 | |
| Intercept Pharmaceuticals, INC. | $114.38 | 2019-2025 | Ocaliva |
| Sk Life Science, INC. | $114.35 | 2021 | |
| Celgene Corporation | $100.89 | 2022 | |
| Merck Sharp & Dohme LLC | $95.57 | 2023-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $91.54 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $91.54 | 2022-2025 | Ibsrela |
| Conmed Corporation | $89.92 | 2025 | Conmed Biliary, Conmed Polypectomy |
| Redhill Biopharma INC. | $85.66 | 2021-2022 | |
| Madrigal Pharmaceuticals | $83.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $75.60 | 2019-2023 | Sutab |
| Aimmune Therapeutics, INC. | $50.62 | 2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $39.16 | 2022-2023 | |
| Allergan, INC. | $32.34 | 2019 | |
| Exact Sciences Corporation | $31.82 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $30.71 | 2025 | Terlivaz |
| Intra-Sana Laboratories | $21.98 | 2022 | |
| Concordia Pharmaceuticals INC. | $20.08 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.68 | 2019 | |
| Dynavax Technologies Corporation | $13.55 | 2021 | |
| Mylan Institutional INC. | $13.44 | 2023 | Hulio |
| Laborie Medical Technologies Corp. | $10.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Karne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.